Safety of inhaled long-acting anti-muscarinic agents in COPD

References

• Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease. 2017. [cited 2017 February 27] Available from: http://goldcopd.org/gold-2017-global-strategy-diagnosis-management-prevention-copd/
   Google Scholar
• Scott LJ, Hair P. Umeclidinium/Vilanterol: first global approval. Drugs. 2014;74(3):389–395.
   PubMed Web of Science ®Google Scholar
• Montuschi P, Ciabattoni G. Bronchodilating drugs for chronic obstructive pulmonary disease: current status and future trends. J Med Chem. 2015;58(10):4131–4164.
   PubMed Web of Science ®Google Scholar
• LaForce C, Feldman G, Spangenthal S, et al. Efficacy and safety of twice-daily glycopyrrolate in patients with stable, symptomatic COPD with moderate-to-severe airflow limitation: the GEM1 study. Int J Chron Obstruct Pulmon Dis. 2016;11:1233–1243.
   PubMed Web of Science ®Google Scholar
• Barnes PJ. The role of anticholinergics in chronic obstructive pulmonary disease. Am J Med. 2004;117:Suppl 12A:24S-32S.
   PubMed Web of Science ®Google Scholar
• Alagha K, Palot A, Sofalvi T, et al. Long-acting muscarinic receptor antagonists for the treatment of chronic airway diseases. Ther Adv Chronic Dis. 2014;5(2):85–98.
   PubMedGoogle Scholar
• Buels KS, Fryer AD. Muscarinic receptor antagonists: effects on pulmonary function. Handb Exp Pharmacol. 2012;208:317–341.
   Google Scholar
• Gosens R, Zaagsma J, Meurs H, et al. Muscarinic receptor signaling in the pathophysiology of asthma and COPD. Respir Res. 2006;7:73.
   PubMed Web of Science ®Google Scholar
• Ali-Melkkila T, Kanto J, Iisalo E. Pharmacokinetics and related pharmacodynamics of anticholinergic drugs. Acta Anaesthesiol Scand. 1993;37(7):633–642.
   PubMed Web of Science ®Google Scholar
• Lee CH, Choi S, Jang EJ, et al. Inhaled bronchodilators and the risk of tachyarrhythmias. Int J Cardiol. 2015;190:133–139.
   PubMed Web of Science ®Google Scholar
• Wise RA, Anzueto A, Calverley P, et al. The tiotropium safety and performance in respimat trial (TIOSPIR), a large scale, randomized, controlled, parallel-group trial-design and rationale. Respir Res. 2013;14:40.
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359(15):1543–1554.
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Leimer I, Metzdorf N, et al. Cardiac safety of tiotropium in patients with cardiac events: a retrospective analysis of the UPLIFT(R) trial. Respir Res. 2015;16:65.
   PubMed Web of Science ®Google Scholar
• Dahl R, Kaplan A. A systematic review of comparative studies of tiotropium Respimat(R) and tiotropium HandiHaler(R) in patients with chronic obstructive pulmonary disease: does inhaler choice matter? BMC Pulm Med. 2016;16(1):135.
   PubMed Web of Science ®Google Scholar
• Karner C, Chong J, Poole P. Tiotropium versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012;7:CD009285.
   PubMed Web of Science ®Google Scholar
• Price D, Sharma A, Cerasoli F. Biochemical properties, pharmacokinetics and pharmacological response of tiotropium in chronic obstructive pulmonary disease patients. Expert Opin Drug Metab Toxicol. 2009;5(4):417–424.
   PubMed Web of Science ®Google Scholar
• Yohannes AM, Connolly MJ, Hanania NA. Ten years of tiotropium: clinical impact and patient perspectives. Int J Chron Obstruct Pulmon Dis. 2013;8:117–125.
   PubMed Web of Science ®Google Scholar
• Yohannes AM, Willgoss TG, Vestbo J. Tiotropium for treatment of stable COPD: a meta-analysis of clinically relevant outcomes. Respir Care. 2011;56(4):477–487.
   PubMed Web of Science ®Google Scholar
• Caillaud D, Le Merre C, Martinat Y, et al. A dose-ranging study of tiotropium delivered via Respimat Soft Mist Inhaler or HandiHaler in COPD patients. Int J Chron Obstruct Pulmon Dis. 2007;2(4):559–565.
   PubMedGoogle Scholar
• Van Noord JA, Cornelissen PJ, Aumann JL, et al. The efficacy of tiotropium administered via Respimat Soft Mist Inhaler or Handihaler in COPD patients. Respir Med. 2009;103(1):22–29.
   PubMed Web of Science ®Google Scholar
• Ichinose M, Fujimoto T, Fukuchi Y. Tiotropium 5μg via Respimat and 18μg via HandiHaler; efficacy and safety in Japanese COPD patients. Respir Med. 2010;104(2):228–236.
   PubMed Web of Science ®Google Scholar
• Hohlfeld JM, Sharma A, Van Noord JA, et al. Pharmacokinetics and pharmacodynamics of tiotropium solution and tiotropium powder in chronic obstructive pulmonary disease. J Clin Pharmacol. 2014;54(4):405–414.
   PubMed Web of Science ®Google Scholar
• D’Urzo AD, Kerwin EM, Chapman KR, et al. Safety of inhaled glycopyrronium in patients with COPD: a comprehensive analysis of clinical studies and post-marketing data. Int J Chron Obstruct Pulmon Dis. 2015;10:1599–1612.
   PubMed Web of Science ®Google Scholar
• Bateman ED, Chapman KR, Singh D, et al. Aclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respir Res. 2015;16:92.
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease. 2016. [cited 2016 Sept 29] Available from: http://goldcopd.org/global-strategy-diagnosis-management-prevention-copd-2016/
   Google Scholar
• Fink JB, Colice GL, Hodder R. Inhaler devices for patients with COPD. Copd. 2013;10(4):523–535.
   PubMedGoogle Scholar
• Labiris NR, Dolovich MB. Pulmonary drug delivery. Part II: the role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol. 2003;56(6):600–612.
   PubMed Web of Science ®Google Scholar
• Rau JL. Practical problems with aerosol therapy in COPD. Respir Care. 2006;51(2):158–172.
   PubMed Web of Science ®Google Scholar
• Lareau SCRNMSF, Hodder RMDF. Teaching inhaler use in chronic obstructive pulmonary disease patients. J Am Acad Nurse Pract. 2011;24(2):113–120.
   PubMed Web of Science ®Google Scholar
• Lareau SC, Yawn BP. Improving adherence with inhaler therapy in COPD. Int J Chron Obstruct Pulmon Dis. 2010;5:401–406.
   PubMedGoogle Scholar
• Boehringer Ingelheim International GmbH. SPIRIVA® 18 microgram, inhalation powder, hard capsule.Summary of Product Characteristics. 2014. [cited 2016 Sept 29] Available from: https://www.boehringer-ingelheim.com/products/prescription_medicines/respiratory/copd/spiriva/public/images/Spiriva-COPD-HandiHaler-and-Respimat-August_2014.pdf
   Google Scholar
• Boehringer Ingelheim Pharmaceuticals Inc. Prescribing Information: SPIRIVA® RESPIMAT® (tiotropium bromide) Inhalation Spray For Oral Inhalation. 2016. [cited 2016 Sept 29] Available from: http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing+Information/PIs/Spiriva+Respimat/spirivarespimat.pdf
   Google Scholar
• Novartis Europharm Ltd. Summary of Product Characteristics: Seebri Breezhaler 44 micrograms inhalation powder, hard capsules (glycopyrronium bromide). 2012. [cited 2015 06 January] Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002430/WC500133769.pdf
   Google Scholar
• GlaxoSmithKline UK. Summary of Product Characteristics: Incruse® 55 micrograms inhalation powder (umeclidinium bromide). 2014. [cited 2016 Sept 29] Available from: http://ec.europa.eu/health/documents/community-register/2014/20140428128339/anx_128339_en.pdf
   Google Scholar
• Almirall SA Summary of Product Characteristics: Eklira Genuair 322 micrograms inhalation powder (aclidinium bromide). 2012. [cited 2016 Sept 29] Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002211/WC500132661.pdf
   Google Scholar
• Donohue JF, Kalberg C, Shah P, et al. Dose response of umeclidinium administered once or twice daily in patients with COPD: a pooled analysis of two randomized, double-blind, placebo-controlled studies. J Clin Pharmacol. 2014;54(11):1214–1220.
   PubMed Web of Science ®Google Scholar
• Trivedi R, Richard N, Mehta R, et al. Umeclidinium in patients with COPD: a randomised, placebo-controlled study. Eur Respir J. 2014;43(1):72–81.
   PubMed Web of Science ®Google Scholar
• D’Urzo A, Ferguson GT, Van Noord JA, et al. Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial. Respir Res. 2011;12:156.
   PubMed Web of Science ®Google Scholar
• Kerwin E, Hebert J, Gallagher N, et al. Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study. Eur Respir J. 2012;40(5):1106–1114.
   PubMed Web of Science ®Google Scholar
• Beeh KM, Singh D, Di Scala L, et al. Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial. Int J Chron Obstruct Pulmon Dis. 2012;7:503–513.
   PubMed Web of Science ®Google Scholar
• Jones PW, Singh D, Bateman ED, et al. Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study. Eur Respir J. 2012;40(4):830–836.
   PubMed Web of Science ®Google Scholar
• Kerwin EM, D’Urzo AD, Gelb AF, et al. Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I). Copd. 2012;9(2):90–101.
   PubMedGoogle Scholar
• Montuschi P, Macagno F, Valente S, et al. Inhaled muscarinic acetylcholine receptor antagonists for treatment of COPD. Curr Med Chem. 2013;20(12):1464–1476.
   PubMed Web of Science ®Google Scholar
• Anderson P. Use of Respimat Soft Mist inhaler in COPD patients. Int J Chron Obstruct Pulmon Dis. 2006;1(3):251–259.
   PubMedGoogle Scholar
• Zierenberg B. Optimizing the in vitro performance of Respimat. J Aerosol Med. 1999;12(Suppl 1):S19–24.
   PubMedGoogle Scholar
• Hochrainer D, Holz H, Kreher C, et al. Comparison of the aerosol velocity and spray duration of Respimat Soft Mist Inhaler and pressurized metered dose inhalers. J Aerosol Med. 2005;18(3):273–282.
   PubMedGoogle Scholar
• Brand P, Hederer B, Austen G, et al. Higher lung deposition with Respimat Soft Mist Inhaler than HFA-MDI in COPD patients with poor technique. Int J Chron Obstruct Pulmon Dis. 2008;3(4):763–770.
   PubMedGoogle Scholar
• Maltais F, Milot J. The potential for aclidinium bromide, a new anticholinergic, in the management of chronic obstructive pulmonary disease. Ther Adv Respir Dis. 2012;6(6):345–361.
   PubMed Web of Science ®Google Scholar
• Vogelmeier C, Hederer B, Glaab T, et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med. 2011;364(12):1093–1103.
   PubMed Web of Science ®Google Scholar
• Boehringer Ingelheim Pharmaceuticals Inc. SPIRIVA® HANDIHALER® (tiotropium bromide inhalation powder), for oral inhalation use. 2004. [cited 2017 March 10] Available from: http://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Spiriva/Spiriva.pdf
   Google Scholar
• European Medicines Agency. Seebri Breezhaler (Glycopyrronium) product characteristics. 2012. [cited 2017 10 March] Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002430/WC500133769.pdf
   Google Scholar
• GlaxoSmithKline US. Incruse Ellipta (Umeclidinium inhalation powder 62.5 mcg) prescribing information. 2013. [cited 2017 March 13] Available from: https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Incruse_Ellipta/pdf/INCRUSE-ELLIPTA-PI-PIL.PDF
   Google Scholar
• U.S. Food and Drug Administration. TUDORZA PRESSAIR (aclidinium bromide inhalation powder) prescribing information. 2012. [cited 2017 March 13] Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202450s000lbl.pdf
   Google Scholar
• Tashkin DP. The safety of anticholinergic bronchodilators for the treatment of chronic obstructive pulmonary disease. Expert Opin Drug Saf. 2015;14(11):1759–1772.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Page CP, Calzetta L, et al. Pharmacology and therapeutics of bronchodilators. Pharmacol Rev. 2012;64(3):450–504.
   PubMed Web of Science ®Google Scholar
• Tashkin DP. Long-acting anticholinergic use in chronic obstructive pulmonary disease: efficacy and safety. Curr Opin Pulm Med. 2010;16(2):97–105.
   PubMed Web of Science ®Google Scholar
• Feinberg M. The problems of anticholinergic adverse effects in older patients. Drugs Aging. 1993;3(4):335–348.
   PubMed Web of Science ®Google Scholar
• Hall SK. Acute angle-closure glaucoma as a complication of combined beta-agonist and ipratropium bromide therapy in the emergency department. Ann Emerg Med. 1994;23(4):884–887.
   PubMed Web of Science ®Google Scholar
• Aalbers R, Maleki-Yazdi MR, Hamilton A, et al. Randomized, double-blind, dose-finding study for tiotropium when added to olodaterol, administered via the respimat((R)) inhaler in patients with chronic obstructive pulmonary disease. Adv Ther. 2015;32(9):809–822.
   PubMed Web of Science ®Google Scholar
• Donohue JF, Niewoehner D, Brooks J, et al. Safety and tolerability of once-daily umeclidinium/vilanterol 125/25 mcg and umeclidinium 125 mcg in patients with chronic obstructive pulmonary disease: results from a 52-week, randomized, double-blind, placebo-controlled study. Respir Res. 2014;15:78.
   PubMed Web of Science ®Google Scholar
• Singh D, Jones PW, Bateman ED, et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study. BMC Pulm Med. 2014;14:178.
   PubMed Web of Science ®Google Scholar
• D’Urzo AD, Rennard SI, Kerwin EM, et al. Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study. Respir Res. 2014;15:123.
   PubMed Web of Science ®Google Scholar
• Salpeter SR, Ormiston TM, Salpeter EE. Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis. Chest. 2004;125(6):2309–2321.
   PubMed Web of Science ®Google Scholar
• Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356(8):775–789.
   PubMed Web of Science ®Google Scholar
• Ferguson GT, Funck-Brentano C, Fischer T, et al. Cardiovascular safety of salmeterol in COPD. Chest. 2003;123(6):1817–1824.
   PubMed Web of Science ®Google Scholar
• Boehringer Ingelheim International GmbH. Summary of Product Characteristics: Spiriva Respimat 2.5 microgram, solution for inhalation. 2014. [cited 2016 Sept 29] Available from: http://www.boehringer-ingelheim.com/products/prescription_medicines/respiratory/asthma/spiriva/public/images/14-3946-Blatter-SPC-Spiriva-ERS.pdf
   Google Scholar
• Paul KJ, Walker RL, Dublin S. Anticholinergic medications and risk of community-acquired pneumonia in elderly adults: a population-based case-control study. J Am Geriatr Soc. 2015;63(3):476–485.
   PubMed Web of Science ®Google Scholar
• Tricco AC, Strifler L, Veroniki AA, et al. Comparative safety and effectiveness of long-acting inhaled agents for treating chronic obstructive pulmonary disease: a systematic review and network meta-analysis. BMJ Open. 2015;5(10):e009183.
   PubMed Web of Science ®Google Scholar
• Berger WE, Nadel JA. Efficacy and safety of formoterol for the treatment of chronic obstructive pulmonary disease. Respir Med. 2008;102(2):173–188.
   PubMed Web of Science ®Google Scholar
• Fuso L, Mores N, Valente S, et al. Long-acting beta-agonists and their association with inhaled corticosteroids in COPD. Curr Med Chem. 2013;20(12):1477–1495.
   PubMed Web of Science ®Google Scholar
• Gershon A, Croxford R, Calzavara A, et al. Cardiovascular safety of inhaled long-acting bronchodilators in individuals with chronic obstructive pulmonary disease. JAMA Intern Med. 2013;173(13):1175–1185.
   PubMed Web of Science ®Google Scholar
• Calzetta L, Rogliani P, Matera MG, et al. A systematic review with meta-analysis of dual bronchodilation with LAMA/LABA for the treatment of stable COPD. Chest. 2016;149(5):1181–1196.
   PubMed Web of Science ®Google Scholar
• Sharafkhaneh A, Majid H, Gross NJ. Safety and tolerability of inhalational anticholinergics in COPD. Drug Healthc Patient Saf. 2013;5:49–55.
   PubMedGoogle Scholar
• Kesten S, Jara M, Wentworth C, et al. Pooled clinical trial analysis of tiotropium safety. Chest. 2006;130(6):1695–1703.
   PubMed Web of Science ®Google Scholar
• Halpin DM, Dahl R, Hallmann C, et al. Tiotropium HandiHaler((R)) and Respimat((R)) in COPD: a pooled safety analysis. Int J Chron Obstruct Pulmon Dis. 2015;10:239–259.
   PubMed Web of Science ®Google Scholar
• Barr RG, Bourbeau J, Camargo CA, et al. Tiotropium for stable chronic obstructive pulmonary disease: a meta-analysis. Thorax. 2006;61(10):854–862.
   PubMed Web of Science ®Google Scholar
• Singh S, Loke YK, Enright PL, et al. Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials. Bmj. 2011;342:d3215.
   PubMed Web of Science ®Google Scholar
• Hanania NA. Evaluating the safety of COPD medications: an evidence-based review. Chest. 2013;144(4):1357–1367.
   PubMed Web of Science ®Google Scholar
• Michele TM, Pinheiro S, Iyasu S. The safety of tiotropium–the FDA’s conclusions. N Engl J Med. 2010;363(12):1097–1099.
   PubMed Web of Science ®Google Scholar
• Wise RA, Anzueto A, Cotton D, et al. Tiotropium Respimat inhaler and the risk of death in COPD. N Engl J Med. 2013;369(16):1491–1501.
   PubMed Web of Science ®Google Scholar
• Loke YK, Singh S, Furberg CD. Tiotropium and the risk of death in COPD. N Engl J Med. 2014;370(5):480–481.
   PubMed Web of Science ®Google Scholar
• Dong YH, Lin HH, Shau WY, et al. Comparative safety of inhaled medications in patients with chronic obstructive pulmonary disease: systematic review and mixed treatment comparison meta-analysis of randomised controlled trials. Thorax. 2013;68(1):48–56.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Calzetta L, Rogliani P, et al. Tiotropium formulations and safety: a network meta-analysis. Ther Adv Drug Saf. 2017;8(1):17–30.
   PubMed Web of Science ®Google Scholar
• Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA. 2008;300(12):1439–1450.
   PubMed Web of Science ®Google Scholar
• Lahousse L, Verhamme KM, Stricker BH, et al. Cardiac effects of current treatments of chronic obstructive pulmonary disease. Lancet Respir Med. 2016;4(2):149–164.
   PubMed Web of Science ®Google Scholar
• Buhl R, Banerji D. Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD. Int J Chron Obstruct Pulmon Dis. 2012;7:729–741.
   PubMed Web of Science ®Google Scholar
• Rodrigo GJ, Neffen H, Systematic A. Review of the efficacy and safety of a fixed-dose combination of umeclidinium and vilanterol for the treatment of COPD. Chest. 2015;148(2):397–407.
   PubMed Web of Science ®Google Scholar
• Rennard SI, Scanlon PD, Ferguson GT, et al. ACCORD COPD II: a randomized clinical trial to evaluate the 12-week efficacy and safety of twice-daily aclidinium bromide in chronic obstructive pulmonary disease patients. Clin Drug Investig. 2013;33(12):893–904.
   PubMed Web of Science ®Google Scholar
• Jones PW. Clinical potential of aclidinium bromide in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2015;10:677–687.
   PubMed Web of Science ®Google Scholar
• Albertson TE, Harper R, Murin S, et al. Patient considerations in the treatment of COPD: focus on the new combination inhaler umeclidinium/vilanterol. Patient Prefer Adherence. 2015;9:235–242.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Molimard M. The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPD. Pulm Pharmacol Ther. 2010;23(4):257–267.
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Ferguson GT. Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease. Respir Res. 2013;14:49.
   PubMed Web of Science ®Google Scholar
• Buhl R, Maltais F, Abrahams R, et al. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4). Eur Respir J. 2015;45(4):969–979.
   PubMed Web of Science ®Google Scholar
• Muruganandan S, Jayaram L. Profile of a fixed-dose combination of tiotropium/olodaterol and its potential in the treatment of COPD. Int J Chron Obstruct Pulmon Dis. 2015;10:1179–1189.
   PubMed Web of Science ®Google Scholar
• Pelaia G, Vatrella A, Busceti MT, et al. Pharmacologic rationale underlying the therapeutic effects of tiotropium/olodaterol in COPD. Ther Clin Risk Manag. 2015;11:1563–1572.
   PubMed Web of Science ®Google Scholar
• Bateman ED, Mahler DA, Vogelmeier CF, et al. Recent advances in COPD disease management with fixed-dose long-acting combination therapies. Expert Rev Respir Med. 2014;8(3):357–379.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Calzetta L, Matera MG. Aclidinium/formoterol fixed-dose combination for the treatment of chronic obstructive pulmonary disease. Drugs Today (Barc). 2015;51(2):97–105.
   PubMed Web of Science ®Google Scholar
• Matera MG, Rogliani P, Calzetta L, et al. Safety considerations with dual bronchodilator therapy in COPD: an update. Drug Saf. 2016;39(6):501–508.
   PubMed Web of Science ®Google Scholar
• ZuWallack R, Allen L, Hernandez G, et al. Efficacy and safety of combining olodaterol Respimat((R)) and tiotropium HandiHaler((R)) in patients with COPD: results of two randomized, double-blind, active-controlled studies. Int J Chron Obstruct Pulmon Dis. 2014;9:1133–1144.
   PubMed Web of Science ®Google Scholar
• Calzetta L, Ciaprini C, Puxeddu E, et al. Olodaterol + tiotropium bromide for the treatment of COPD. Expert Rev Respir Med. 2016 Mar 22:1–8. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Kozielski J. Cardiovascular safety of two bronchodilators’ fixed-dose combination: indacaterol and glycopyrronium. Pneumonol Alergol Pol. 2015;83(2):164–170.
   PubMedGoogle Scholar
• Mahler DA, Kerwin E, Ayers T, et al. FLIGHT1 and FLIGHT2: efficacy and safety of QVA149 (Indacaterol/Glycopyrrolate) versus its monocomponents and placebo in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2015;192(9):1068–1079.
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Banerji D, Chapman KR, et al. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. N Engl J Med. 2016;374(23):2222–2234.
   PubMed Web of Science ®Google Scholar
• Zheng J, Zhong N, Newlands A, et al. Efficacy and safety of once-daily inhaled umeclidinium/vilanterol in Asian patients with COPD: results from a randomized, placebo-controlled study. Int J Chron Obstruct Pulmon Dis. 2015;10:1753–1767.
   PubMed Web of Science ®Google Scholar
• Feldman G, Walker RR, Brooks J, et al. 28-Day safety and tolerability of umeclidinium in combination with vilanterol in COPD: a randomized placebo-controlled trial. Pulm Pharmacol Ther. 2012;25(6):465–471.
   PubMed Web of Science ®Google Scholar
• Siler TM, Donald AC, O’Dell D, et al. A randomized, parallel-group study to evaluate the efficacy of umeclidinium/vilanterol 62.5/25 mug on health-related quality of life in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2016;11:971–979.
   PubMed Web of Science ®Google Scholar
• Malerba M, Radaeli A, Montuschi P, et al. Vilanterol trifenatate for the treatment of COPD. Expert Rev Respir Med. 2016;10(7):719–731.
   PubMed Web of Science ®Google Scholar
• Donohue JF, Worsley S, Zhu CQ, et al. Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations. Respir Med. 2015;109(7):870–881.
   PubMed Web of Science ®Google Scholar
• Maleki-Yazdi MR, Kaelin T, Richard N, et al. Efficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: results of a 24-week, randomized, controlled trial. Respir Med. 2014;108(12):1752–1760.
   PubMed Web of Science ®Google Scholar
• Donohue JF, Soong W, Wu X, et al. Long-term safety of aclidinium bromide/formoterol fumarate fixed-dose combination: results of a randomized 1-year trial in patients with COPD. Respir Med. 2016;116:41–48.
   PubMed Web of Science ®Google Scholar
• Matera MG, Sanduzzi A, Cazzola M. Specific role of combination aclidinium: formoterol in the treatment of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2016;11:73–79.
   PubMed Web of Science ®Google Scholar
• Kew KM, Seniukovich A. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2014;3:CD010115.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Matera MG. Triple combinations in chronic obstructive pulmonary disease - is three better than two? Expert Opin Pharmacother. 2014;15(17):2475–2478.
   PubMed Web of Science ®Google Scholar
• Frith PA, Thompson PJ, Ratnavadivel R, et al. Glycopyrronium once-daily significantly improves lung function and health status when combined with salmeterol/fluticasone in patients with COPD: the GLISTEN study, a randomised controlled trial. Thorax. 2015;70(6):519–527.
   PubMed Web of Science ®Google Scholar
• Sousa AR, Riley JH, Church A, et al. The effect of umeclidinium added to inhaled corticosteroid/long-acting beta2-agonist in patients with symptomatic COPD: a randomised, double-blind, parallel-group study. NPJ Prim Care Respir Med. 2016;26:16031.
   PubMed Web of Science ®Google Scholar
• Singh D, Brooks J, Hagan G, et al. Superiority of “triple” therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD. Thorax. 2008;63(7):592–598.
   PubMed Web of Science ®Google Scholar
• Manoharan A, Short PM, Anderson WJ, et al. Impact of long-acting bronchodilators and exposure to inhaled corticosteroids on mortality in COPD: a real-life retrospective cohort study. Lung. 2014;192(5):649–652.
   PubMed Web of Science ®Google Scholar
• Montuschi P, Malerba M, Macis G, et al. Triple inhaled therapy for chronic obstructive pulmonary disease. Drug Discov Today. 2016;21(11):1820–1827.
   PubMed Web of Science ®Google Scholar
• Hughes AD, Chin KH, Dunham SL, et al. Discovery of muscarinic acetylcholine receptor antagonist and beta 2 adrenoceptor agonist (MABA) dual pharmacology molecules. Bioorg Med Chem Lett. 2011;21(5):1354–1358.
   PubMed Web of Science ®Google Scholar
• Hughes AD, Jones LH. Dual-pharmacology muscarinic antagonist and beta(2) agonist molecules for the treatment of chronic obstructive pulmonary disease. Future Med Chem. 2011;3(13):1585–1605.
   PubMed Web of Science ®Google Scholar
• Wielders PL, Ludwig-Sengpiel A, Locantore N, et al. A new class of bronchodilator improves lung function in COPD: a trial with GSK961081. Eur Respir J. 2013;42(4):972–981.
   PubMed Web of Science ®Google Scholar
• Bateman ED, Kornmann O, Ambery C, et al. Pharmacodynamics of GSK961081, a bi-functional molecule, in patients with COPD. Pulm Pharmacol Ther. 2013;26(5):581–587.
   PubMed Web of Science ®Google Scholar
• Farne HA, Cates CJ. Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2015;10:CD008989.
   Google Scholar
• Van Der Molen T, Cazzola M. Beyond lung function in COPD management: effectiveness of LABA/LAMA combination therapy on patient-centred outcomes. Prim Care Respir J. 2012;21(1):101–108.
   PubMedGoogle Scholar
• Blair HA, Deeks ED. Umeclidinium/vilanterol: a review of its use as maintenance therapy in adults with chronic obstructive pulmonary disease. Drugs. 2015;75(1):61–74.
   PubMed Web of Science ®Google Scholar
• Toy EL, Beaulieu NU, McHale JM, et al. Treatment of COPD: relationships between daily dosing frequency, adherence, resource use, and costs. Respiratory Medicine. 2011;105(3):435–441.
   PubMed Web of Science ®Google Scholar
• Izquierdo JL, Paredero JM, Piedra R. Relevance of dosage in adherence to treatment with long-acting anticholinergics in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2016;11:289–293.
   PubMed Web of Science ®Google Scholar
• Moitra S, Bhome AB, Brashier BB. Aclidinium bromide/formoterol fixed-dose combination therapy for COPD: the evidence to date. Drug Des Devel Ther. 2015;9:1989–1999.
   PubMed Web of Science ®Google Scholar
• Donohue JF, Singh D, Munzu C, et al. Magnitude of umeclidinium/vilanterol lung function effect depends on monotherapy responses: results from two randomised controlled trials. Respir Med. 2016;112:65–74.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Calzetta L, Ora J, et al. Searching for the synergistic effect between aclidinium and formoterol: from bench to bedside. Respir Med. 2015;109(10):1305–1311.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Calzetta L, Page CP, et al. Pharmacological characterization of the interaction between aclidinium bromide and formoterol fumarate on human isolated bronchi. Eur J Pharmacol. 2014;745:135–143.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Calzetta L, Puxeddu E, et al. Pharmacological characterisation of the interaction between glycopyrronium bromide and indacaterol fumarate in human isolated bronchi, small airways and bronchial epithelial cells. Respir Res. 2016;17(1):70.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Calzetta L, Segreti A, et al. Translational study searching for synergy between glycopyrronium and indacaterol. Copd. 2015;12(2):175–181.
   PubMedGoogle Scholar
• Oba Y, Sarva ST, Dias S. Efficacy and safety of long-acting beta-agonist/long-acting muscarinic antagonist combinations in COPD: a network meta-analysis. Thorax. 2016;71(1):15–25.
   PubMed Web of Science ®Google Scholar
• Calzetta L, Matera MG, Cazzola M. Pharmacological interaction between LABAs and LAMAs in the airways: optimizing synergy. Eur J Pharmacol. 2015;761:168–173.
   PubMed Web of Science ®Google Scholar